Under the "microscope" of the police authorities is the sudden death of the director of the Neurology Clinic of the 424 General Military Hospital, in Thessaloniki.
They found him dead in his office
The unfortunate doctor was found dead in his office on Wednesday (23/9) by his colleagues, who immediately notified the Police.
A year after discontinuation, patients were finally able to maintain about a quarter of the initial loss. A similar picture has been recorded with tirzepatide. At the same time, some of the improvements that had occurred in blood pressure, sugar and other metabolic markers also began to subside.
Is there a limit to usage?
There is currently no specific rule that says that one must take GLP-1 for five, ten or twenty years. The duration of treatment depends on each patient, their response to the drug, side effects and their overall health status.
However, experts now treat obesity as a chronic disease. This means that, as with other chronic conditions, treatment may need to be continued for a long time. For many, continuing treatment may be how the effect is maintained.
Now, GLP-1s have now been used in a very large number of people and there is important data on their effectiveness and safety. Nevertheless, scientific knowledge about their use over many decades continues to evolve. The most common side effects involve the digestive system, such as nausea, vomiting, diarrhea, or constipation. There are also rarer but more serious complications, which is why treatment needs medical supervision.
What happens to the benefits for the heart
Stopping GLP-1 slimming medications can lead to a rapid loss of their cardiovascular health benefits. According to a new study, two years after stopping treatment is associated with up to a 22% higher risk of serious cardiovascular events.
Researchers from Washington University School of Medicine in St. Louis followed more than 333,000 American veterans with type 2 diabetes for three years. They found that stopping or intermittent use of GLP-1 drugs for just six months was associated with a significant increase in the risk of serious cardiovascular events, compared to those who were normally on treatment. The findings were published in the scientific journal BMJ Medicine.
The longer patients remained untreated, the more the risk increased. After two years without treatment with GLP-1, the risk of heart attack, stroke or death was up to 22% higher than those who continued treatment. In other words, much of the cardiovascular protection that had been achieved during treatment seemed to be lost, as reported by Science Daily.
